Co-infection: liver transplantation in HIV-positive persons
1 June 2003. Related: Hepatitis coinfection, On the web.
2003
Catalogue of FDA approved drug products
1 June 2003. Related: On the web.
Volume 4 Number 5 June 2003 PDF
1 June 2003. Related: PDFs.
Volume 4 Number 4 May 2003
1 May 2003. Related: Editorial.
4th International Workshop on Clinical Pharmacology of HIV Therapy, 27-29 March 2003, Cannes, France
1 May 2003. Related: Conference reports, PK and drug interactions.
Can low NVP plasma concentrations explain the results seen in the EFV and NVP containing arms of the NARVAL study?
1 May 2003. Related: Conference reports, PK and drug interactions.
Up to one third of patients receiving standard doses of NNRTIs may be being underdosed
1 May 2003. Related: Conference reports, PK and drug interactions.
Nelfinavir concentrations are significantly higher in HIV/HCV co-infected patients with cirrhosis
1 May 2003. Related: Conference reports, PK and drug interactions.
Less diarrhoea and bioequivalence with the new nelfinavir 625mg tablet
1 May 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions, Side effects.
The potential for probenecid to have a serious interaction with HIV-1 protease inhibitors
1 May 2003. Related: Conference reports, PK and drug interactions, Side effects.
PK studies reveal significant sex/gender differences
1 May 2003. Related: Conference reports, Women's health, PK and drug interactions.
Pregnancy-related PK studies
1 May 2003. Related: Conference reports, Pregnancy, PK and drug interactions.
New test to measure intracellular levels of nucleosides
1 May 2003. Related: Conference reports, PK and drug interactions.
Case studies for therapeutic drug monitoring (TDM)
1 May 2003. Related: Conference reports, PK and drug interactions.
Launch of guide to the use of drug level monitoring
1 May 2003. Related: Conference reports, PK and drug interactions.
10th Conference on Retroviruses and Opportunistic Infections (CROI), 10-14 February 2003, Boston, USA
1 May 2003. Related: Conference reports.
Pharmacokinetic papers from 10th CROI
1 May 2003. Related: Conference reports, PK and drug interactions.
Pediatric studies from 10th CROI
1 May 2003. Related: Conference reports, Women's health, Pregnancy, Paediatric care.
T-20 access programme to continue in UK for a further two months
1 May 2003. Related: Antiretrovirals.
Durability and success capability of HAART: 4.5 years follow-up
1 May 2003. Related: Antiretrovirals.
Older HIV-positive patients in the era of HAART: changing of a scenario
1 May 2003. Related: Antiretrovirals.
Immune reconstitution in older HIV-positive individuals
1 May 2003. Related: Antiretrovirals, Treatment strategies.
The City turns up the heat on drug companies to make treatment available in poorest countries
1 May 2003. Related: Treatment access.
Lancet commentary concludes that prevention and treatment in South Africa are affordable and desirable
1 May 2003. Related: Treatment access.
South Africa treatment protests go global
1 May 2003. Related: Treatment access.
Gilead to sell tenofovir at cost to 68 countries
1 May 2003. Related: Treatment access.
New advocacy coalition demands emergency funding from rich governments for Global Fund
1 May 2003. Related: Treatment access.
Statins and fibrates both relatively effective for PI-induced hyperlipidemia
1 May 2003. Related: Lipodystrophy and metabolic complications.
Pioglitazone subjectively improves body shape abnormalities
1 May 2003. Related: Lipodystrophy and metabolic complications.
Study reveals new reverse transcriptase mutations
1 May 2003. Related: Drug resistance.
Tissue T-cell analysis represents renewed challenge to ‘tap and drain’ orthodoxy
1 May 2003. Related: Basic science and immunology.
Integrating nutrition therapy into medical management of HIV: a supplement of Clinical Infectious Diseases
1 May 2003. Related: Nutrition.
BHIVA HIV/hepatitis B and HIV/hepatitis C co-infection guidelines (2003): posted to web for consultation
1 May 2003. Related: Hepatitis coinfection.
Index of biochemical markers could reduce need for biopsy by half in HIV/HCV co-infected patients
1 May 2003. Related: Hepatitis coinfection.
HCV protects against abnormal blood lipids in HAART-treated HIV patients
1 May 2003. Related: Hepatitis coinfection.
HCV levels in semen
1 May 2003. Related: Hepatitis coinfection.
38th Annual Meeting of the European Association for the Study of the Liver (EASL)
1 May 2003. Related: On the web.
First European HIV Drug Resistance Workshop
1 May 2003. Related: On the web.
Further Coverage of 10th Retrovirus Conference
1 May 2003. Related: On the web.
Medscape articles
1 May 2003. Related: On the web.
Newsletters and journals: IAPAC Monthly, AIDS Treatment News, STEP Perspective, PRN Notebook, Hopkins HIV Report, GHMC Treatment Issues, TAG Line
1 May 2003. Related: On the web.
Nutritional Care Manual for HIV-positive people
1 May 2003. Related: On the web.
Volume 4 Number 4 May 2003 PDF
1 May 2003. Related: PDFs.
Volume 4 Number 3 April 2003
1 April 2003. Related: Editorial.
10th Conference on Retroviruses and Opportunistic Infections (CROI), 10-14 February 2003, Boston, USA
1 April 2003. Related: Conference reports.
Pipeline compounds in Phase 2/3 Studies
1 April 2003. Related: Conference reports, Antiretrovirals.
96-week results show tenofovir-including regimen has side-effect advantages over d4T regimen in treatment naïve patients
1 April 2003. Related: Conference reports, Antiretrovirals.
2NN results – nevirapine and efavirenz in prospective randomised head-to-head study
1 April 2003. Related: Conference reports, Antiretrovirals.
NIH/NIAID study of generic drugs shows results consistent with stringent manufacturing standards
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment access, PK and drug interactions.
Treatment interruptions: cycles, pauses, are just plain stopping?
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Conference has strong emphasis on women
1 April 2003. Related: Conference reports, Women's health, Lipodystrophy and metabolic complications, Cancer and HIV.
Tenofovir and renal tubular dysfunction
1 April 2003. Related: Conference reports, Side effects.
Approaches to treatment of lipodystrophy
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Surgery for buffalo hump shows variable results depending on method
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Other studies – nucleosides and switching to abacavir; importance of lipoatrophy and buffalo hump
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
HAART to HEART: cardiovascular risk in HIV
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Alendronate, vitamin D and calcium are safe and effective treatment for HIV-associated bone loss
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Bone loss and fat loss are closely related in HIV patients on HAART
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected patients
1 April 2003. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
12-week response predicts which HIV-HCV coinfected patients will not benefit from continued pegylated interferon plus ribavirin
1 April 2003. Related: Conference reports, Hepatitis coinfection.
Pegylated interferon associated with eye disorders
1 April 2003. Related: Conference reports, Side effects, Hepatitis coinfection.
Nevirapine resistance – the cautionary tales continue
1 April 2003. Related: Conference reports, Pregnancy, Drug resistance.
Global Fund gives $210 million for treatment in Thailand
1 April 2003. Related: Treatment access.
Anti-HIV combination drug for Indonesia
1 April 2003. Related: Treatment access.
Indian generic drug maker Ranbaxy Laboratories to launch own-brand abacavir
1 April 2003. Related: Treatment access.